Monday, September 1, 2025

HistoIndex Advances Fibrosis Assessment with FibroSIGHT™ Plus

Related stories

Uniphore Acquires Orby AI and Autonom8

Uniphore, a leader in Business AI, announced the acquisition...

Belden Unveils Next-Gen Connectivity & Cybersecurity Tools

New product releases include extended Ethernet reach and advanced...

Virtualitics Iris: AI Agents Driving Mission Readiness

Virtualitics, the Mission AI company specializing in next-generation readiness...

Horizon3.ai Unveils Endpoint Security in NodeZero

Horizon3.ai, a global leader in offensive security, has announced...
spot_imgspot_img

HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™, which debuted just months earlier, FibroSIGHT™ Plus introduces an additional feature of automated quantitative analysis of fibrosis- a key advancement that enables more consistent and precise characterization at diagnosis and tracking of fibrosis in patients with Metabolic Dysfunction-associated Steatohepatitis (MASH). “We’re thrilled to deliver another advancement in MASH diagnostics, bridging our experience and capabilities in clinical trials all the way to clinical use.”, said Yukti Choudhury, Chief Development Officer at HistoIndex.

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img